Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann
From Oncology Brothers: Practice-Changing Cancer Discussions · · 24 min
This plays from the publisher's own server. We do not host a copy.
Description
Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.
Join us as we explored:
- The critical distinction between primary and secondary myelofibrosis and its implications for treatment
- The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis
- Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept
- The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs
- The importance of spleen reduction and its correlation with patient outcomes and survival
- Insights into the side effect profiles of various treatments and the future of myelofibrosis management
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem